We are live on ! Find out more
ARNA

Arena Pharmaceuticals Inc

Delisted

ARNA was delisted on the 10th of March, 2022.

140 hedge funds and large institutions have $571M invested in Arena Pharmaceuticals Inc in 2013 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 54 increasing their positions, 37 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

46% more repeat investments, than reductions

Existing positions increased: 54 | Existing positions reduced: 37

37% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 19

4% more funds holding

Funds holding: 134140 (+6)

27% less capital invested

Capital invested by funds: $787M → $571M (-$216M)

38% less call options, than puts

Call options by funds: $34.7M | Put options by funds: $56.2M

Holders
140
Holders Change
+6
Holders Change %
+4.48%
% of All Funds
4.54%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.03%
New
26
Increased
54
Reduced
37
Closed
19
Calls
$34.7M
Puts
$56.2M
Net Calls
-$21.6M
Net Calls Change
-$9.28M
Name Holding Trade Value Shares
Change
Change in
Stake
Barclays
51
Barclays
United Kingdom
$749K -$788K -11,734 -44%
VOYA Investment Management
52
VOYA Investment Management
Georgia
$725K
SCM
53
Stevens Capital Management
Pennsylvania
$716K +$691K +10,285 +312%
T
54
TradeWorx
New Jersey
$700K +$892K +13,284 New
DCM
55
Dialectic Capital Management
Connecticut
$659K +$580K +8,633 +223%
AQR Capital Management
56
AQR Capital Management
Connecticut
$655K -$880K -13,106 -51%
DekaBank Deutsche Girozentrale
57
DekaBank Deutsche Girozentrale
Germany
$640K +$816K +12,150 New
CBOA
58
Commonwealth Bank of Australia
Australia
$629K +$226K +3,370 +39%
Royal Bank of Canada
59
Royal Bank of Canada
Ontario, Canada
$616K +$697K +10,381 +792%
PA
60
Profund Advisors
Maryland
$602K +$28.1K +419 +4%
RA
61
Rational Advisors
New York
$553K
USAA
62
United Services Automobile Association
Texas
$546K +$263K +3,920 +61%
LPL Financial
63
LPL Financial
California
$533K +$58.8K +875 +8%
TMAM
64
Tokio Marine Asset Management
Japan
$523K +$666K +9,920 New
U
65
UBS
Switzerland
$518K -$713K -10,615 -52%
SC
66
Sculptor Capital
New York
$499K +$635K +9,460 New
RFC
67
Russell Frank Company
Washington
$440K +$47.9K +714 +9%
ARTA
68
A.R.T. Advisors
New York
$434K +$554K +8,251 New
T. Rowe Price Associates
69
T. Rowe Price Associates
Maryland
$432K -$105K -1,570 -16%
UBS AM
70
UBS AM
Illinois
$431K
Zurich Cantonal Bank
71
Zurich Cantonal Bank
Switzerland
$422K
EMG
72
Ellington Management Group
Connecticut
$379K +$483K +7,200 New
Principal Financial Group
73
Principal Financial Group
Iowa
$377K +$82.1K +1,223 +21%
Cambridge Investment Research Advisors
74
Cambridge Investment Research Advisors
Iowa
$343K +$6.71K +100 +2%
NPC
75
National Planning Corporation
California
$305K +$19.8K +295 +5%

ARNA Hedge Fund Activity: Q3 2013 in Review

140 of the 3,084 institutional investors tracked by Wall St. Rank reported a position in Arena Pharmaceuticals Inc (ARNA) for Q3 2013, worth a combined $571M — down 27% from $787M a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new ARNA positions and 19 closed out — a net gain of 7 holders — while 54 added to existing stakes and 37 trimmed.

The largest buyer was Wellington Management Group, adding an estimated $17.9M. The largest seller was Federated Hermes, exiting entirely with an estimated $20.3M sold.

  • 140 institutional investors held Arena Pharmaceuticals Inc (ARNA) as of Q3 2013, up from 134 in Q2 2013.
  • Funds reported $571M of Arena Pharmaceuticals Inc stock for Q3 2013, down 27% quarter-over-quarter.
  • 26 funds opened new Arena Pharmaceuticals Inc positions in Q3 2013 and 19 closed out, a net change of +7 holders.
  • The largest Arena Pharmaceuticals Inc buyer in Q3 2013 was Wellington Management Group, an estimated $17.9M added.
  • The largest Arena Pharmaceuticals Inc seller in Q3 2013 was Federated Hermes, an estimated $20.3M sold.

Based on aggregated 13F filings for Q3 2013.